|
An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome Clinical research trials and An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome. An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome clinical trial. Test subjects oftentimes recieve the best healthcare possible for their An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome  An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
For Condition: Acute Myeloid Leukemia,Myelodysplastic Syndrome
Status: Recruiting
Sponsor(s): Novartis Pharmaceuticals , Dana-Farber/Harvard Cancer Center,Memorial Sloan-Kettering Cancer Center,M.D. Anderson Cancer Center
Synopsis: Patients who agree to participate in this trial will be screened for the FLT 3 mutation. If positive they will have a physical exam, blood test, EKG, chest x-ray, bone marrow aspirate and a pregnancy test. Patients will be required to have weekly blood test and bone marrow aspirate monthly.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients: with AML who are not candidates for myelosuppressive chemotherapy or with AML who have relapsed disease or are refractory to standard therapy and not likely to require cytoreductive therapy within one month or with MDS subtypes RAEB, RAEB-T or CMML. - Who 0-2 - FLT 3 mutation - AML (MDS patients exempted) must have a total WBC (including blast) of > 5,000 - Patients must have a serum creatinine of < 1.5 x ULN, SGOT/SGPT < 3 x ULN and total bilirubin < 2.0 x ULN
Total Enrollment: 20
Location and Contact Information:
M.D. Anderson Cancer Center *Not yet recruiting*
Houston, Texas,
United States
Not yet recruiting Eli Estey 713-792-7544
Memorial Sloan Kettering Cancer Center *Recruiting*
New York City, New York,
United States
Recruiting Virginia Klimek 212-639-6519
Dana-Farber Cancer Institute *Recruiting*
Boston, Massachusetts,
United States
Recruiting Ilene Galinsky 617-632-3902
Additional Information:
Study ID Numbers: PKC4122104;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045942
Other Myelodysplastic Syndrome Studies:
1. Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
2. Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
3. Study of the Safety and Efficacy of CC-5013 Treatment For Patients with Myelodysplastic Syndrome
4. An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
5. Clofarabine combinations in relapsed/refractory AML, MDS and myeloid blast phase CML
Related Studies:
Other Myelodysplastic Syndrome Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
|
|
|
|
|
|
|
|
